Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.71 |
| ▸ | CA12 | O43570 | 5/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 8/20 | 0.61 |
| ▸ | HTR1A | P08908 | 7/20 | 0.61 |
| ▸ | HTR2A | P28223 | 7/20 | 0.61 |
| ▸ | HTR7 | P34969 | 7/20 | 0.61 |
| ▸ | HTR6 | P50406 | 7/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | DRD5 | P21918 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | ELANE | P08246 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354797 | 1.00 | CA9 (0.71) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL6324557 | 0.98 | CA9 (0.73) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL8973563 | 0.94 | CA9 (0.72) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL30872949 | 0.87 | CA12 (0.71) | CA9CA12CA2ELANE | |
| SCHEMBL9437884 | 0.87 | CA12 (0.71) | CA9CA12CA2ELANE | |
| SCHEMBL29621871 | 0.85 | CA9 (0.97) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL14560535 | 0.85 | CA9 (0.97) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL29739791 | 0.85 | CA9 (0.71) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL9826952 | 0.83 | CA9 (0.73) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL17329453 | 0.83 | CA9 (0.73) | CA9CA12HDAC1HDAC2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854870-B1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2003-10-23 | — | — | US | disclosed |
| EP-0633260-B1 | 2,3-Dihydro-1,4-benzodioxan-5-yl-piperazine derivatives having 5-HT1A-antagonistic activity | DUPHAR INT RES (NL) | 2001-11-07 | — | — | EP | disclosed |
| US-6083949-A | FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR | MERCK & CO., INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5717100-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5462942-A | 2,3-dihydro-1,4-benzodioxin-5-yl-piperazine derivatives having 5-HT 1A-antagonistic activity | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1995-10-31 | — | — | US | disclosed |
| EP-0633260-A1 | 2,3-Dihydro-1,4-benzodioxin-5-yl-piperazine derivatives having 5-HT1A-antagonistic activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1995-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | CA9 4236/4885CA12 3272/4885HDAC1 1075/4885 |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | GALR1, GALNT1, GALK1 | CA9 3137/4885CA12 2849/4885HDAC1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.